Specify a stock or a cryptocurrency in the search bar to get a summary
Oncorus Inc
ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. Address: 50 Hampshire Street, Cambridge, MA, United States, 02139
Analytics
WallStreet Target Price
5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ONCR
Dividend Analytics ONCR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-5 %Dividend History ONCR
Stock Valuation ONCR
Financials ONCR
Results | 2019 | Dynamics |